Pazopanib in Molecularly Selected Patients With Advanced NSCLC
Status:
Terminated
Trial end date:
2019-12-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how participants with advanced non-small cell lung
cancer (NSCLC) that have certain abnormalities in the pazopanib target genes respond to
pazopanib treatment.